- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.11. | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update | 89 | PR Newswire |
Completed enrollment of the randomized Phase 1b cohorts of the ongoing ENABLE trial of ELVN-001 in CML
Remains on track to initiate Phase 3 pivotal trial of ELVN-001... ► Artikel lesen | |
| 12.11. | Enliven Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.08. | Enliven Therapeutics, Inc Q2 Loss Climbs | 1 | RTTNews | ||
| 13.08. | Enliven Therapeutics GAAP EPS of -$0.49 beats by $0.04 | 2 | Seeking Alpha | ||
| ENLIVEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.08. | Enliven Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13.08. | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | 272 | PR Newswire | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks... ► Artikel lesen | |
| 25.06. | Enliven Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.06. | TD Cowen bekräftigt Kaufempfehlung für Enliven Therapeutics-Aktie | 1 | Investing.com Deutsch | ||
| 20.06. | TD Cowen reiterates buy rating on Enliven Therapeutics stock | 1 | Investing.com | ||
| 16.06. | Goldman Sachs initiates Enliven Therapeutics stock with Buy rating | 1 | Investing.com | ||
| 13.06. | Enliven Therapeutics prices $200 million public offering | 1 | Investing.com | ||
| 13.06. | Enliven Therapeutics stock falls after pricing capital raise of $200M via securities offering | 1 | Seeking Alpha | ||
| 13.06. | Enliven Therapeutics announces $200 million public offering | 5 | Investing.com | ||
| 13.06. | Enliven Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.06. | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress | 384 | PR Newswire | Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
| 14.05. | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | 539 | PR Newswire | Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June
EHA abstract reported cumulative MMR rate... ► Artikel lesen | |
| 14.05. | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress | 614 | PR Newswire | Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
| 13.03. | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update | 1.018 | PR Newswire | Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues
Expected monotherapy and combination data from the ELVN-002 Phase 1... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,752 | -0,48 % | Valneva veröffentlicht finale Phase-2-Studiendaten für Borreliose-Impfstoff | Der französische Impfstoffhersteller Valneva hat finale Daten aus der Phase-2-Studie VLA15-221 für seinen Lyme-Borreliose-Impfstoffkandidaten VLA15 vorgelegt. Die Ergebnisse zeigen, dass die Antikörperwerte... ► Artikel lesen | |
| BIOFRONTERA | 2,600 | -2,99 % | PTA-news: Biofrontera AG: Biofrontera berichtet über die Ergebnisse der ersten neun Monate des Jahres 2025 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DER ERSTEN NEUN MONATE DES JAHRES 2025
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 44,600 | +0,45 % | Crispr Therapeutics pares loss amid takeover speculation | ||
| AFFIMED | 0,972 | 0,00 % | NSE - Affimed N.V. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| DENALI THERAPEUTICS | 15,415 | +0,42 % | Denali Therapeutics Inc.: Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) | SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,885 | +2,34 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates | Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate... ► Artikel lesen | |
| AGIOS | 23,400 | 0,00 % | Cantor Fitzgerald bestätigt "Overweight"-Rating für Agios Pharma Aktie | ||
| CELLECTIS | 4,195 | +1,08 % | Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update | Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel Process... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,410 | +5,57 % | Voyager Therapeutics, Inc.: Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia | CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular... ► Artikel lesen | |
| UNIQURE | 21,750 | -0,23 % | uniQure Inc.: uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update | ~ Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington's disease met its primary and key secondary endpoints, demonstrating statistically significant slowing of disease progression... ► Artikel lesen | |
| ENZO BIOCHEM | 0,388 | 0,00 % | Battery Ventures Completes Take-Private of Enzo Biochem | Apter joins as CEO to support the next stage of growth for the life-science reagents platform
BOSTON--(BUSINESS WIRE)--Battery Ventures, a global, technology-focused investment firm, announced the... ► Artikel lesen | |
| TECTONIC THERAPEUTIC | 19,020 | -7,08 % | TECX, GKOS, GH, ALGN, NMRA Surge After Hours On Clinical Data And Earnings | WASHINGTON (dpa-AFX) - Several healthcare and life sciences names posted notable gains in after-hours trading, driven by clinical updates, earnings releases, and in some cases, unexplained momentum.Tectonic... ► Artikel lesen | |
| SCILEX | 18,750 | -2,55 % | Datavault AI schließt zweite Bitcoin-Investmenttranche von Scilex ab | ||
| ALLOGENE THERAPEUTICS | 1,340 | -2,19 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting | SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR... ► Artikel lesen | |
| NUVATION BIO | 7,480 | -5,02 % | H.C. Wainwright reiterates Buy rating on Nuvation Bio stock at $10 target |
ENLIVEN THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 20,560 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENLIVEN THERAPEUTICS INC finden Sie auf Wallstreet Online.